touchCONGRESS Holistic approaches to patient care in nAMD
Watch this two-part activity discussing the latest developments in the clinical management of neovascular age-related macular degeneration (nAMD), filmed following the European Society of Retina Specialists (EURETINA) 2020 Virtual Congress
Part 1: Watch internationally renowned expert Prof. Anat Loewenstein review the key data on nAMD from the congress Watch Now
Part 2: Choose from leading experts who discuss what the data means for global and regional practice Select An Interview
Introduction
Retinal fluid as a marker of disease activity in nAMD
Treatment discontinuation: Why it occurs and how to reduce it
Optimal dosing of anti-VEGF in nAMD: Clinical trial and real-world experience
Overview
Watch Prof. Anat Loewenstein, a leading ophthalmologist, review the latest data on the clinical management of neovascular age-related macular degeneration (nAMD) from the European Society of Retina Specialists (EURETINA) 2020 Virtual Congress.
Anat Loewenstein, MD, is Professor of Ophthalmology, Vice Dean of the Faculty of Medicine and Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at Tel Aviv University, and Chairman of the Division of Ophthalmology at the Tel Aviv Medical Center, Tel Aviv, Israel. read more
Her main field of interest is the investigation of drug administration and toxicity to the retina, early detection of macular degeneration and home monitoring of disease. Prof. Loewenstein has led the development of novel technologies for the early detection of macular degeneration, including automated technology for the detection of retinal disease activity and augmented virtual reality to replace the operating microscope, as well as the development of home optical coherence tomography.
Prof. Loewenstein has published 400 papers in peer-reviewed journals and contributed to multiple chapters in ophthalmology textbooks. She has multiple roles in the most prominent retina societies. Today, Prof. Loewenstein serves on the International committee of the Macula Society and is currently the General Secretary of the European Society of Retina Specialists (EURETINA). In addition, she serves as the Editor in Chief of the journal Case Reports in Ophthalmology, is an associate editor of the European Journal of Ophthalmology and of Ophthalmologica.
In Israel, she serves as the president of the Israeli Ophthalmological Society and as chair of the Ministry of Health’s ethics committee. In addition, she is a member of the National Council of Surgery and Anaesthesia. Prof. Loewenstein has received multiple international awards, including the Rosenthal and Michelson Awards and the Arnall Patz Medal of the Macula Society, and the Silver Fellow Medal of the Association for Research in Vision and Ophthalmology (ARVO).
Prof. Anat Loewenstein discloses: Consultant/Advisory Board fees from Allergan, Bayer, Novartis, Notal Vision, Syneos Health
Find out how the latest data from the European Society of Retina Specialists (EURETINA) 2020 Virtual Congress may influence the management of patients with neovascular age-related macular degeneration.
Find out how the latest data from the European Society of Retina Specialists (EURETINA) 2020 Virtual Congress may influence the management of patients with neovascular age-related macular degeneration.
Find out how the latest data from the European Society of Retina Specialists (EURETINA) 2020 Virtual Congress may influence the management of patients with neovascular age-related macular degeneration (nAMD).
Please Select A Video:
Overview & Learning Objectives
Overview
In this activity, internationally recognized experts in ophthalmology discuss the latest data on the clinical management of neovascular age-related macular degeneration (nAMD), including the use of retinal fluid as a marker of disease activity, the factors that impact treatment adherence and discontinuation, and optimal dosing strategies for anti-vascular endothelial growth factor (VEGF) therapy in nAMD, based on clinical trial and real-world experience.
Learning Objectives
After watching this activity, participants should be better able to:
- Evaluate the use of retinal fluid as a marker of disease activity in neovascular age-related macular degeneration (nAMD)
- Recognize the impact of factors that contribute to treatment discontinuation and evaluate ways to reduce the treatment burden in nAMD
- Interpret results from clinical trials and real-world experience to inform on optimal dosing of anti-vascular endothelial growth factor (VEGF) therapy in nAMD
Register to touchOPHTHALMOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
